LEIDEN, the Netherlands, Feb. 07, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to
changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic
fibrosis (CF) and Leber's congenital amaurosis Type 10 (LCA10), today announced that Daniel de Boer, Chief Executive Officer and
Smital Shah, Chief Financial Officer, will take part in an analyst led fireside chat during the LEERINK Partners Global Healthcare
Conference on Wednesday, February 15, 2017 at 3:00pm ET. The conference is being held at the Lotte New York Palace in New York, NY,
USA.
The live and archived webcast of the presentation will be accessible from the ‘Investor Relations’ section of ProQR’s website
(www.proqr.com) under ‘Events and Presentations’. The archived webcast will be available for 30
days following the presentation date.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of
severe orphan diseases such as cystic fibrosis and Leber’s congenital amaurosis. Based on our unique proprietary RNA repair
platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
Contact:
Sariette Witte
Investor Relations
T: +1 213 261 8891
ir@proqr.com
